Clinical and genotypic features, renal prognosis of orphan tubulopathies with nephrocalcinosis and cystin stones in children

THE AIM: To evaluate clinical and genotypic features, renal prognosis in orphan tubulopathies with nephrocalcinosis and cys- tine calculi in 22 pediatric patients. PATIENTS AND METHODS: The study included 22 patients (from 1 year 4 months to 17 years 11 months) with orphan tubulopathies with nephrocalcinosis (22) and cystinuria, cystine stones (2). Of the 22 probands, there were 14 (63.6 %) boys and 8 (36.4 %) girls. Clinical, biochemical, imaging, and molecular genetic diagnostic methods were used. The severity of chronic kidney disease was stratified according to the K/DOQI classification (2002). RESULTS: A genetic study of 22 children with nephrocalcinosis revealed primary hyperoxaluria of types I, II, III (AGXT, GRHPR, HOGA1) in 5; familial hypomagnesemia with hypercalciuria and nephrocalcinosis (CLDN16) in 5; hypophosphatemic rickets with hypercal- ciuria and nephrocalcinosis (SLC34A3) in 3; Bartter type I syndrome (SLC12A1) in 1 and Bartter syndrome type IV (BSND) in 1, Dent1 disease (CLCN5) in 1, Dent disease 2 (OCRL) in 1, idiopathic infantile hypercalcemia type I (SLC34A1) in 1 and type II (CYP24A1) in 2. Based on the detection of mutations in the SLC3A1 and SLC7A9 genes, 2 probands were diagnosed with type I and non type I cystinuria. The features of gene mutation variants in 22 children with orphan tubulopathies with nephrocalci- nosis and cystinuria, and cystine nodules were identified. A study of kidney function in 22 children over the age of 2 years with nephrocalcinosis and cystinuria revealed CKD C1 with normal glomerular filtration rate (17), CKD C2, C3, C4 (5). A girl with familial hypomagnesemia with hypercalciuria and nephrocalcinosis due to a mutation of the CLDN16 gene, progression CKD of С1 to C4, underwent kidney transplantation at the age of 18 before starting dialysis. CONCLUSION: Features of the clinical phenotype and variants of mutations of genes of orphan tubulopathies with nephrocalcinosis and cystinuria, cystine stones in 22 children were established. Progression of CKD from C1 with normal glomerular filtration rate to C2, C3, C4 was ascertained from 22 in 5 children (25) % with primary hyperoxaluria type1 (1), hypomagnesemia with calciuria and nephrocalcinosis (3), Dent-2 Disease (1). Identification of gene mutations in molecular genetic studies in children with nephrocalcinosis and cys- tinuria establishes a clinical and genetic diagnosis, the pathogenesis of an orphan tubulopathy, and determines personalized management based on individual genetic characteristics.

1. An online catalog of human genes and genetic disorders [Electronic resource]. https://omim.org/. Ссылка активна 17.07.2025

2. The portal for rare diseases and orphan drugs: https://www.orpha.net/.https://omim.org/. Ссылка активна 17.07.2025

3. Groothoff JW, Metry E, Deesker L, Garrelfs S, Acquaviva C, Almardini R, Beck BB, Boyer O et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope. Nat Rev Nephrol 2023;19(3):194–211. doi: 10.1038/s41581-022-00661-1

4. Bakkaloğlu SA, Büyükkaragöz B, Pınarbaşı AS, Leventoğlu E, Saygılı S, Çomak E et al. Comprehensive evaluation of patients with primary hyperoxaluria type 1: A nationwide study. Nephrology (Carlton) 2024;29(4):201–213. doi: 10.1111/nep.14273

5. Michael M, Harvey E, Milliner DS, Frishberg Y, Sas DJ, Calle J, Copelovitch L, Penniston KL, Saland J, Somers MJG, Baum MA. Diagnosis and management of primary hyperoxaluria: best practices. Pediatr Nephrol 2024;39(11):3143–3155. doi: 10.1007/s00467-024-06328-2

6. Martin-Higueras C, Borghese L, Torres A, Fraga-Bilbao F, Santana-Estupiñán R et al. Multicenter Long-Term Real World Data on Treatment With Lumasiran in Patients With Primary Hyperoxaluria Type 1. Kidney Int Rep 2023;9(1):114–133. doi: 10.1016/j.ekir.2023.10.004

7. Saffe S, Doerry K, Büscher AK, Hansen M, Rohmann M, Kanzelmeyer N, Latta K, Kemper MJ, Loos S. Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1. Pediatr Nephrol 2025 Jun;40(6):1929–1937. doi: 10.1007/s00467-025-06665-w

8. Gang X, Liu F, Mao J.Lumasiran for primary hyperoxaluria type 1: What we have learned? Front Pediatr 2023;10:1052625. doi: 10.3389/fped.2022.105262

9. Abid A. Possible ethnic associations in primary hyperoxaluria type-III-associated HOGA1 sequence variants. Mol Biol Rep 2021;48(4):3841–3844. doi: 10.1007/s11033-021-06380-3

10. Julius M, Lavsky HS, Kalfon L et al. Primary hyperoxaluria type 3: from infancy to adulthood in a genetically unique cohort. Pediatr Nephrol 2025;40:731–741. https://doi.org/10.1007/s00467-024-06536-w

11. Shee K, Stoller ML. Perspectives in primary hyperoxaluria - historical, current and future clinical interventions. Nat Rev Urol 2022;19 (3):137–146. doi: 10.1038/s41585-021-00543-4

12. Pediatric Nephrology. Editors Francesco Emma, Stuart L. Goldstein, Arvind Bagga, Carlton M. Bates, Rukshana Shroff.© Springer Nature Switzerland 2022;2130 https:2022;//doi.org/10.1007/978-3-030-52719-8

13. Metry EL, van Dijk LMM, Peters-Sengers H, Oosterveld MJS, Groothoff JW, Ploeg RJ, Stel VS, Garrelfs SF. Transplantation outcomes in patients with primary hyperoxaluria: a systematic review. Pediatr Nephrol 2021;36(8):2217–2226. doi: 10.1007/s00467-021-05043-6

14. Amiryan MO, Leviashvili JG, Savenkova ND. Primary hyperoxaluriaof types I, II, III in children (literature review). Nephrology (Saint-Petersburg) 2023;27(1):18–30. (In Russ.) https://doi.org/10.36485/1561-6274-2023-27-1-18-30

15. Vall-Palomar M, Madariaga L, Ariceta G. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Pediatr Nephrol 2021;36(10):3045–3055. doi: 10.1007/s00467-021-04968-2

16. Rahmani N, Talebi S, Hooman N, Karamzade A. Familial Hypomagnesemia with, Nephrocalcinosis, and Bilateral Chorioretinal Atrophy in a Patient with Homozygous p.G75S Variant in CLDN19. J Pediatr Genet 2021; 10(3):230–235. doi: 10.1055/s-0041-1733852

17. Eltan M, Yavas Abali Z, Turkyilmaz A, Gokce I, Abali S. et al. Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis Due to CLDN16 Gene Mutations: Novel Findings in Two Cases with Diverse Clinical Features. Calcif Tissue Int 2022;110(4):441–450. doi: 10.1007/s00223-021-00928

18. Perdomo-Ramirez A, Aguirre M, Davitaia T, Ariceta G, Ramos-Trujillo E et al Renal Tube Group; Claverie-Martin F. Characterization of two novel mutations in the claudin-16 and claudin-19 genes that cause familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Gene 2019;689:227–234. doi: 10.1016/j.gene.2018.12.02430576809

19. Yuan T, Pang Q, Xing X, Wang X, Li Y, Li J, Wu X, Li M, Wang O, Jiang Y, Dong J, Xia W. First report of a novel missense CLDN19 mutations causing familial hypomagnesemia with hypercalciuria and nephrocalcinosis in a Chinese family. Calcif Tissue Int 2015;96(4):265–273. doi: 10.1007/s00223-014-9951-7

20. Savenkova ND, Leviashvili ZhG, Andreeva EF, Semenova OA, Papayan KA. Hereditary kidney disease in children. Edited by N.D. Savenkova. Levsha Publishing House LLC. St. Petersburg, SPb., 2020; 440. (In Russ.)

21. Zelikovic I. and Aude Servai A. Aminoaciduria and Glycosuria in Children. Pediatric Nephrology. Editors Francesco Emma, Stuart L. Goldstein, Arvind Bagga, Carlton M. Bates, Rukshana Shroff. © Springer Nature Switzerland AG.2022;39:929–956. https:2022;//doi.org/10.1007/978-3-030-52719-8_33

22. Liu D, Zhao Y, Xue X, Hou X, Xu H, Zhao X, Tian Y, Tang W, Guo J, Xu CNovel compound heterozygous pathogenic variants in the SLC3A1 gene in a Chinese family with cystinuria. BMC Med Genomics 2023;16(1):333. doi: 10.1186/s12920-023-01767-6

23. Liu L, Xu Z, Guan Y, Zhang Y, Li X, Ren Y, Hu L Clinical Characteristics and In Silico Analysis of Cystinuria Caused by a Novel SLC3A1 Mutation. Yan X. Genes (Basel) 2022 21;13(11):2173. doi: 10.3390/genes13112173

24. Bai P, Zhang W, Lai L, Huang H, Qin J, Duan B, Wang H, Chen Y, Jia Y, Xing J, Wang T, Chen B. Declaration: Novel SLC3A1 mutation in a cystinuria patient with xanthine stones: a case report. BMC Urol 2023:31;23(1):130. doi: 10.1186/s12894-023-01300

25. Leviashvili JG, Savenkova ND, Lyubimova OV, Levi NL, Karpova TV, Amiryan MO. Orphan hereditary hypophosphatemic rickets with hypercalcemia, nephrocalcinosis due to mutation of the SLC34A3 gene. Nephrology (Saint-Petersburg) 2021;25(3):52–60 (In Russ.) doi: 10.36485/1561-6274-2021-25-3-52-60

26. Haffner D and Agnes Linglar A. Renal Hypophosphatemia.Pediatric Nephrology. Editors Francesco Emma, Stuart L. Goldstein, Arvind Bagga, Carlton M. Bates, Rukshana Shroff. © Springer Nature Switzerland AG.2022; 40: 957–986. https:2022;//doi.org/10.1007/978-3-030-52719-8_44

27. Chi Y, Zhao Z, He X, Sun Y, Jiang Y, Li M, Wang O, Xing X, Sun AY, Zhou X, Meng X, Xia W. A compound heterozygous mutation in SLC34A3 causes hereditary hypophosphatemic rickets with hypercalciuria in a Chinese patient. Bone 2014;59:114–121. doi: 10.1016/j.bone.2013.11.008

28. Nwachukwu C, Singh G, Moore B, Strande NT, Bucaloiu ID, Chang AR. Risk of Nephrolithiasis in Adults Heterozygous for SLC34A3 Ser192Leu in an Unselected Health System Cohort. J Am Soc Nephrol 2023 Nov 1;34(11):1819–1821. doi: 10.1681/ASN.0000000000000204

29. Wagner C, Hernando N, Forster I, Biber J, Murer H. Genetic defect in renal phosphate handing. In Genetic Diseases of the kidney. Eds: R Lipton, S Somlo, G Giebsch, D Seldin. ELSEVIER 2009;43:715–734

30. Nizar R, Cantley NWP, Tang JCY. Infantile hypercalcaemia type 1: a vitamin D-mediated, under-recognised cause of hypercalcaemia. Endocrinol Diabetes Metab Case Rep 2021;1(20):21–0058. doi: 10.1530/EDM-21-0058

31. Kurnaz E, Savas Erdeve S, Cetinkaya S, Aycan Z. Rare Cause of Infantile Hypercalcemia: A Novel Mutation in the SLC34A1 Gene. Horm Res Paediatr 2019;91(4):278–284. doi: 10.1159/000492899

32. Acar FA, Isik G, Mutlu M, Kader Ş, Aslan Y, Kalyoncu M. Antenatal Bartter Syndrome Caused by a Novel Homozygous Mutation in SLC12A1 Gene. Indian J Nephrol 2019;29(5):360–363. doi: 10.4103/ijn.IJN_175_18

33. Leviashvili JG, Savenkova ND, Amiryan MA. Tubulopathies with hypokalemic alkalosis: Bartter and HELIX syndromes in children. Ros Vestn Perinatol Pediatr 2023; 68:(3):12–20 (in Russ). doi: 10.21508/1027–4065–2023–68–3–12–2

34. Yi S, Li M, Yang Q, Zhang X, Chen F, Qin Z, Yi S, Huang L, Wei H, Zhang Q, Luo J. Novel SLC12A1 mutations cause Bartter syndrome in two patients with different prognoses. Clin Chim Acta 2022 1;(531):120–125. doi: 10.1016/j.cca.2022.03.025

35. Devuyst O, Zennaro MC, Vargas-Poussou R, Satlin LM. Inherited Disorders of Sodium and Potassium Handling. Pediatric Nephrology. Ed.: Emma F, Goldstein S, Bagga A, Bates CM, Shroff R. Springer, Berlin, Heidelberg. 2022; 987–1032. doi: 10.1007/978–3–642–27843–3_108–1

36. Burballa C, Cantero-Recasens G, Prikhodina L, Lugani F, Schlingmann K et al. DENT study group. Clinical and genetic characteristics of Dent's disease type 1 in Europe. Nephrol Dial Transplant 2023 31;38(6):1497–1507. doi: 10.1093/ndt/gfac310

37. Suarez-Artiles L, Perdomo-Ramirez A, Ramos-Trujillo E, Claverie-Martin F. Splicing Analysis of Exonic OCRL Mutations Causing Lowe Syndrome or Dent-2 Disease. Genes (Basel) 2018 4;9(1):15. doi: 10.3390/genes9010015

38. K/DOQI Kidney Disease Outcomes Quality Initiative. Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation,Classification Stratification. Am J Kidney Dis (AJKD) 2002;39(2) Suppl.1:1–266. doi: 10.1016/S0272-6386(02)70101-7

39. Hogg RJ, Furth S, Lemley KV et al. National Kidney Foundation's Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification and stratification. Pediatrics 2003;111(6):1416–1421. doi: 10.1542/peds.111.6.1416